A small molecule drug is one that can easily enter cells due to its low molecular weight. Once inside the cells, it can interact with other molecules such as proteins and cause cancer cells to die. This is in contrast to drugs with a high molecular weight, which prevents them from easily entering cells. The pharmaceutical preparation of these small molecule drugs sold in prefilled syringes is known as a small molecule prefilled syringe. Small molecule prefilled syringes are an alternative to other forms of dosage such as capsules and tablets. The solution of active pharmaceutical components is filled into empty glass or polymer and plastic syringes. Prefilled syringe delivery systems are available for drugs in categories such as cardiovascular, neurology, adjuvants, and analgesics. Small molecule prefilled syringes have faster therapeutic action than syringes and tablets, as the drug directly enters the bloodstream.
Global Small Molecule Prefilled Syringes Market - Impact of the Coronavirus (COVID-19) Pandemic
Coronavirus (COVID-19) outbreak was first reported on December 31, 2019, in Wuhan, China. The World Health Organization declared COVID-19 as pandemic on March 11, 2020. According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 213 million cases and 4.48 million deaths due to coronavirus (COVID-19) were reported till August 25, 2021, across the globe.
Impact of COVID-19 on Demand and Supply of Prefilled Syringes
The COVID-19 pandemic and lockdown in various countries across the globe has impacted the financial status of businesses across all sectors including private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry mainly due to strict lockdown in several regions. The COVID-19 pandemic has affected the economy of various regions across the globe in three main ways; 1) by directly affecting the production and demand; 2) by creating disruptions in distribution channels; and 3) through its financial impact on companies and financial markets. Several countries such as Thailand, Indonesia, and Singapore are facing problems with regards to transportation and distribution of healthcare products.
In 2020, the COVID-19 pandemic disrupted health-care delivery around the world, including delay in needle or syringe related diagnosis and treatment. Therefore, the impact of COVID-19 is expected to hamper the growth of global small molecule prefilled syringes market. For instance, according to an article published in International Journal of Drug Policy, September 2020, The Needle and Syringe Programs (NSPs) are organized for marginalized population for free access to injectables and for awareness of the adverse effects associated with injecting drugs. For instance, according to an article published in International Journal of Drug Policy, September 2020, the restrictions due to the pandemic resulted in a 36% decrease in the number of needle and service programs (NSP) clients in England, a 36% decrease in visits, and a 29% decrease in needle distribution as compared to 2019. NSP coverage for those injecting psychoactive drugs was cut in half, falling from 14 needles per week on March 15, 2020, to seven needles per week by mid-April, 2020.
The global small molecule prefilled syringes market is estimated to be valued at US$ 17,419.4 Mn in 2021, and is expected to exhibit a CAGR of 5.5 % over the forecast period (2021-2028).
Figure 1: Global Small Molecule Prefilled Syringes Market Share (%) Analysis, By Drug Class, 2021
The increasing cases of chronic diseases is expected to drive growth of the market over the forecast period.
The emerging prevalence of chronic diseases is expected to bolster the growth of global small molecule prefilled syringes market. For instance, according to the World Health Organization (WHO), cardiovascular diseases (CVDs) are the leading cause of death worldwide. Moreover, in 2019, about 17.9 million people died from CVDs, representing 32% of all global deaths. Of these deaths, 85% were due to heart attack and stroke. Furthermore, according to Centers for Disease Control and Prevention, in 2019, coronary heart disease caused total 659,041 deaths, which is 200 deaths per 100,000 population in the U.S.
Adoption of Self-injection Devices
Main benefits of prefilled syringes over conventional drug delivery systems are improved product safety, self-administration, accurate dosing, and low chances of drug contamination. Self- injection advantage of prefilled syringes is a major factor for increasing adoption of these, thus aiding in growth of the prefilled syringe market globally. For instance, in 2019, Fresenius Kabi AG, a global healthcare company, expanded its Simplist ready-to-administer prefilled syringe portfolio by launching Adenosine Injection in prefilled syringes indicated for the treatment of tachycardia.
|Base Year:||2020||Market Size in 2021:||US$ 17,419.4 Mn|
|Historical Data for:||2017 to 2020||Forecast Period:||2021 to 2028|
|Forecast Period 2021 to 2028 CAGR:||5.5 %||2028 Value Projection:||US$ 25,411.8 Mn|
Sanofi, Viatris Inc. (Mylan N.V.), AstraZeneca Plc, F. Hoffmann-La Roche AG (Genentech, Inc.), Sun Pharmaceutical Industries Ltd., Pfizer Inc., Dr. Reddy’s Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Fresenius Kabi AG, and McKesson Corporation
|Restraints & Challenges:||
Restraint- Global Small Molecule Prefilled Syringes Market
The regulatory authorities are recalling some prefilled syringes due to the increase in their adverse effects such as causing embolism in the body, which is expected to hinder the growth of global small molecule prefilled syringes market over the forecast period. For instance, in August 2021, the U.S. Food and Drug Administration identified Monoject Flush Prefilled Syringes (0.9% sodium chloride) as a Class I recall, the most serious type of recall and use of these devices may cause serious injuries or death. Monoject Flush Prefilled Syringes was marketed by Cardinal Health, a U.S. based multinational health care services company.
Global Small Molecule Prefilled Syringes Market – Regional Analysis
On the basis of region, the global small molecule prefilled syringes market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
North America is expected to hold dominant position in the global small molecule prefilled syringes market over the forecast period, increasing number of inorganic growth strategies such as collaborations between market players. For instance, in April 2019, Schreiner MediPharm, a Germany-based global provider of specialty pharmaceutical labeling solutions, announced collaboration with B. Braun Medical, a medical and pharmaceutical device company. The B Braun launched its prefilled syringe of Heparin Sodium injection, unique selling point (USP) utilizing Schreiner MediPharm’s label-integrated Needle-Trap system in the U.S. market.
Moreover, due to business expansion by investing in manufacturing units by market players, Europe is expected to witness a significant growth in global small molecule prefilled syringes market over the forecast period. For instance, in December 2020, BD (Becton, Dickinson and Company), a leading global medical technology company, announced plans to invest approximately US$ 1.2 billion over a 4-year period to expand and upgrade manufacturing capacity and technology for pre-fillable syringes (PFS) and advanced drug delivery systems (ADDS) across its six global manufacturing locations and add a new manufacturing facility in Spain.
Figure 2: Global Small Molecule Prefilled Syringes Market Value (US$ Mn), by Region, 2021
Global Small Molecule Prefilled Syringes Market – Competitive Landscape
Major players operating in the global small molecule prefilled syringes market include Sanofi, Viatris Inc. (Mylan N.V.), AstraZeneca Plc, F. Hoffmann-La Roche AG (Genentech, Inc.), Sun Pharmaceutical Industries Ltd., Pfizer Inc., Dr. Reddy’s Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Fresenius Kabi AG, and McKesson Corporation.
Prefilled syringes have several advantages over traditional vial packaging, including ease of use. Prefilled syringes obviate the need for the processes that are required before using a drug in a vial. It also helps to eliminate dosing errors because prefilled syringes contain the exact dose. Many pharmaceutical manufacturers overfill vials by up to 25% to ensure that the end user receives the correct dose. However, overfilling can result in errors that are virtually eliminated with prefilled syringes. With the introduction of more expensive biotech drugs, this is advantageous because it means less waste, particularly if some vaccines are in short supply or extremely expensive.
Market players are focused on product launches or approvals, which is expected to contribute to the growth of the global small molecule prefilled syringes market over the forecast period. For instance, in March 2018, Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration (FDA) approved Lucentis (ranibizumab injection) 0.3 mg prefilled syringe (PFS) as a new method of administering the medicine to treat all forms of diabetic retinopathy.
Market players are focused on launching manufacturing capabilities for prefilled syringes. This is expected to drive the market growth over the forecast period. For instance, in July 2019, Terumo Corporation, based in Japan, announced the construction of an additional production facility for pre-filled syringes at its subsidiary Terumo Yamaguchi D&D.
Market players focused on product launches is expected to propel the growth of the global small molecule prefilled syringes market. For instance, in March 2020, Dr. Reddy's Laboratories Ltd., a leading multinational pharmaceutical company, announced the launch of Naloxone Hydrochloride Injection USP, 2 mg/2 mL (1 mg/mL) Single-dose Prefilled Syringe, a therapeutic equivalent generic version of Narcan (naloxone hydrochloride) Injection USP in India.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.